Synovus Financial’s ADMA Biologics ADMA Stock Holding History

Synovus Financial’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,000	Closed	-$9K	–	1557
2020 Q1	$9K	Buy	+3,000	New	+$10.4K	﹤0.01%	1585

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Synovus Financial's ADMA Position: Q2 2020 in Review

Synovus Financial sold out of ADMA Biologics (ADMA) in Q2 2020, closing a stake of 3,000 shares — an estimated $9K sold.

Synovus Financial first reported a position in ADMA in Q1 2020 and held it in 1 quarter. The position peaked at $9K in Q1 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q2 2020.

Synovus Financial reported no remaining ADMA Biologics position as of Q2 2020 after selling out during the quarter.
Synovus Financial sold 3,000 ADMA Biologics shares in Q2 2020, an estimated $9K.
Synovus Financial first reported a position in ADMA Biologics in Q1 2020 and held it in 1 quarter.
Synovus Financial's ADMA Biologics position peaked at $9K in Q1 2020.
95 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2020.

Based on Synovus Financial's 13F filing for Q2 2020, filed 10 Aug 2020.